Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

Exclusion Criteria

• •1. History of any medical condition that would confound the results of the study including but not limited to the following:
• •* Hepatic disease or significant hepatic dysfunction
• •* History of pancreatitis
• •* History of thrombocytopenia
• •* History of glaucoma
• •* History of osteoporosis or osteopenia
• •* Cardiovascular Disease - Coronary artery disease, Ischemic heart disease or Significant Arrhythmia
• •* History of active Cerebrovascular Disease
• •* Hypertension - Uncontrolled hypertension in a non-migrainous state (\> 160 mmHg systolic or \>95 mmHg. diastolic). Hypertension must be controlled effectively with medication for a period of 3 months.
• •* Basilar or Hemiplegic Migraine
• •* Significant peripheral vascular disease or Raynaud's Syndrome
• •* Significant Active Renal, Hepatic, Gastrointestinal, Endocrine or
• •* Neurological Disease
• •* History of depression, mood problems or suicidal thoughts or behavior that in the opinion of the Investigator would interfere with participation in the study.
• •2. History of ergotamine, "triptan", or analgesic abuse within past 3 months
• •3. History of current or recent drug or alcohol abuse that would interfere with participation in the study.
• •4. More than 15 headache days per month within past 3 months.
• •5. Women who are pregnant or breast feeding
• •6. Subjects with known hypersensitivity or intolerance to topiramate or any triptan-like medication
• •7. Subject is scheduled for surgical procedure to occur while enrolled in study.that in opinion of the Investigator would interfere with participation in the study.
• •8. Subject is on a ketogenic diet
• •9. Participation in another investigative drug study within the previous 30 days
• •10. Excluded medications: MAO Inhibitors, lithium, methylergonovine, methysergide, ergotamine-containing products, or topiramate daily for migraine prophylaxis.